Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy...

全面介紹

Na minha lista:
書目詳細資料
發表在:Data Brief
Main Authors: Faehling, Martin, Schumann, Christian, Christopoulos, Petros, Hoffknecht, Petra, Alt, Jürgen, Horn, Marlitt, Eisenmann, Stephan, Schlenska-Lange, Anke, Schütt, Philipp, Steger, Felix, Brückl, Wolfgang M., Christoph, Daniel C.
格式: Artigo
語言:Inglês
出版: Elsevier 2020
主題:
Data Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7750486/
https://ncbi.nlm.nih.gov/pubmed/33364266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2020.106556
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍